Two Updated Clinical Practice Guidelines Are Scheduled for Publication in Summer 2025
By Maureen Corrigan, Director of Clinical Practice Guidelines and Professional & Clinical Affairs
One of the most important functions of the Endocrine Society is to develop and maintain an up-to-date portfolio of Clinical Practice Guidelines (CPGs) that provide relevant, timely, evidence-based recommendations for patient care and clinical practice.
Recognized as a gold standard for endocrine practice, our CPGs are used by clinicians worldwide when making important decisions about patient care. Our CPGs play a critical role in improving healthcare quality, safety, and efficiency while ensuring that endocrine care is based on the best available evidence.
That’s why it is newsworthy when the Society develops a new guideline or updates an existing one. That’s also why we ask our members to weigh in during the CPG development process.
We rely on our members’ vast expertise and experience to ensure these guidelines meet the highest standards of trustworthiness, are as actionable as possible, and have real-world relevance. We also rely on members to identify any gaps or biases in the draft recommendations prior to publication. This rigorous, open process also helps ensure inclusivity and transparency in the development of the recommendations, and it makes our guidelines more likely to be adopted and implemented.
The recommendations from our two upcoming guidelines are in or nearing their public comment period. These guidelines, which are updates of existing topics, are scheduled for publication in the summer of 2025:
Your comments will ensure these CPGs reflect the state of the evidence and meet the needs of practicing clinicians.
For example, in the management of primary aldosteronism (PA), we ask members to comment on clinical workflows such as, “How to Screen for PA in Individuals with Hypertension,” and “Algorithm for the Management of Hypertensive Adults with Aldosterone, Renin, and ARR Suggestive of PA.”
Similar frameworks are available for comment on the updated CPG on diabetes in pregnancy.
If these topics are not in your area of expertise, please keep a look out for future CPGs in the pipeline.
Public comment is only one of the many aspects of the Endocrine Society’s guideline development program that is aimed to ensure full transparency of the recommendations. We recently took steps to ensure our guidelines adhere to the highest standards of trustworthiness.
In 2022, the Endocrine Society published its new updated approach, policies, and more rigorous methodology for guideline development.
These enhancements to the program included: (1) enhanced inclusion of non-endocrinologist experts, including patient representatives, on guideline development panels; (2) implementation of a more rigorous conflict/duality of interest policy; (3) a requirement that all formal recommendations must be demonstrably underpinned by systematic evidence review; (4) the explicit use of GRADE Evidence-to-Decision frameworks; (5) greater use and explanation of standardized guideline language; and (5) a more intentional approach to guideline updating. The new policy also describes some of the experiential differences our guideline readers are most likely to notice.
I invite you to explore 33 CPGs across 12 practice areas. Thank you for your continued support of our CPG program.
